Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat

Surgery

Volumn 144, Issue 1, 2008, Pages 66-73

  Buyne, O R ^a   van Goor, H ^a   Bleichrodt, R P ^a   Verweij, P E ^a   Hendriks, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; INTERLEUKIN 10; INTERLEUKIN 6; STREPTOKINASE; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ABDOMINAL ABSCESS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CULTURE; CELL COUNT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; MACROPHAGE; MALE; NEUTROPHIL; NONHUMAN; PERITONEAL FLUID; PERITONITIS; PRIORITY JOURNAL; RAT; WISTAR RAT;

ABDOMINAL ABSCESS; ANIMALS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; MALE; PERITONITIS; RATS; RATS, WISTAR; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 45049087781     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.03.025     Document Type: Article

References (40)

1. Marshall J.C., and Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 31 (2003) 2228-2237
2. Schein M. Surgical management of intra-abdominal infection: is there any evidence?. Langenbecks Arch Surg 387 (2002) 1-7
3. Bosscha K., van Vroonhoven T.J., and van der Werken C. Surgical management of severe secondary peritonitis. Br J Surg 86 (1999) 1371-1377
4. Sirinek K.R. Diagnosis and treatment of intra-abdominal abscesses. Surg Infect (Larchmt) 1 (2000) 31-38
5. Rosin D., Zmora O., Khaikin M., Bar Z.B., Ayalon A., and Shabtai M. Laparoscopic management of surgical complications after a recent laparotomy. Surg Endosc 18 (2004) 994-996
6. Tomita H., Osada S., Miya K., and Matsuo M. Delayed recurrence of postoperative intra-abdominal abscess: an unusual case and review of the literature. Surg Infect (Larchmt) 7 (2006) 551-554
7. Stewart P.S. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292 (2002) 107-113
8. Worland M.A., Radabaugh R.S., and Mueller B.A. Intraperitoneal thrombolytic therapy for peritoneal dialysis-associated peritonitis. Ann Pharmacother 32 (1998) 1216-1220
9. Duch J.M., and Yee J. Successful use of recombinant tissue plasminogen activator in a patient with relapsing peritonitis. Am J Kidney Dis 37 (2001) 149-153
10. El-Menyar A.A., Altamimi O.M., Gomaa M.M., Dabdoob W., Abbas A.A., Abdel Rahman M.O., et al. Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction. Coron Artery Dis 17 (2006) 431-437
11. Mullen M.T., McGarvey M.L., and Kasner S.E. Safety and efficacy of thrombolytic therapy in postoperative cerebral infarctions. Neurol Clin 24 (2006) 783-793
12. Ueshima S., and Matsuo O. Development of new fibrinolytic agents. Curr Pharm Des 12 (2006) 849-857
13. van Goor H., de Graaf J.S., Kooi K., Sluiter W.J., Bom V.J., van der M.J., et al. Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis. J Am Coll Surg 179 (1994) 407-411
14. Rotstein O.D., and Kao J. Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator. J Infect Dis 158 (1988) 766-772
15. Buyne O.R., Bleichrodt R.P., Verweij P.E., Groenewoud H.M., van Goor H., and Hendriks T. A peritonitis model with low mortality and persisting intraabdominal abscesses. Int J Exp Pathol 87 (2006) 361-368
16. Buyne O.R., Bleichrodt R.P., van Goor H., Verweij P.E., and Hendriks T. Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model. Int J Colorectal Dis 22 (2007) 819-825
17. van Goor H. In vitro studies on the effect of recombinant tissue plasminogen activator on the rat fibrinolytic system. In: Fibrinolytic therapy in generalized peritonitis to prevent intraabdominal absess formation [thesis] Nijmegen, the Netherlands: 1996;125-34.
18. Ahrenholz D.H., and Simmons R.L. Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 88 (1980) 41-47
19. Rotstein O.D. Role of fibrin deposition in the pathogenesis of intraabdominal infection. Eur J Clin Microbiol Infect Dis 11 (1992) 1064-1068
20. Holmdahl L. The role of fibrinolysis in adhesion formation. Eur J Surg Suppl (1997) 24-31
21. Neudecker J., Junghans T., Ziemer S., Raue W., and Schwenk W. Effect of laparoscopic and conventional colorectal resection on peritoneal fibrinolytic capacity: a prospective randomized clinical trial. Int J Colorectal Dis 17 (2002) 426-429
22. Houston K.A., McRitchie D.I., and Rotstein O.D. Tissue plasminogen activator reverses the deleterious effect of infection on colonic wound healing. Ann Surg 211 (1990) 130-135
23. Evans D.M., McAree K., Guyton D.P., Hawkins N., and Stakleff K. Dose dependency and wound healing aspects of the use of tissue plasminogen activator in the prevention of intra-abdominal adhesions. Am J Surg 165 (1993) 229-232
24. Buckenmaier III C.C., Summers M.A., and Hetz S.P. Effect of the antiadhesive treatments, carboxymethylcellulose combined with recombinant tissue plasminogen activator and Seprafilm, on bowel anastomosis in the rat. Am Surg 66 (2000) 1041-1045
25. Bedirli A., Gokahmetoglu S., Sakrak O., Ersoz N., Ayangil D., and Esin H. Prevention of intraperitoneal adhesion formation using beta-glucan after ileocolic anastomosis in a rat bacterial peritonitis model. Am J Surg 185 (2003) 339-343
26. Sikkink C.J., de M.B., Bleichrodt R.P., and van G.H. Auto-cross-linked hyaluronic acid gel does not reduce intra-abdominal adhesions or abscess formation in a rat model of peritonitis. J Surg Res 136 (2006) 255-259
27. Muller S.A., Treutner K.H., Haase G., Kinzel S., Tietze L., and Schumpelick V. Effect of intraperitoneal antiadhesive fluids in a rat peritonitis model. Arch Surg 138 (2003) 286-290
28. Broche F., and Tellado J.M. Defense mechanisms of the peritoneal cavity. Curr Opin Crit Care 7 (2001) 105-116
29. Renckens R., Roelofs J.J., Florquin S., de Vos A.F., Pater J.M., Lijnen H.R., et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol 177 (2006) 1189-1196
30. Martineau L., and Shek P.N. Peritoneal cytokine concentrations and survival outcome in an experimental bacterial infusion model of peritonitis. Crit Care Med 28 (2000) 788-794
31. Montravers P., Maulin L., Mohler J., and Carbon C. Microbiological and inflammatory effects of murine recombinant interleukin-10 in two models of polymicrobial peritonitis in rats. Infect Immun 67 (1999) 1579-1584
32. Sewnath M.E., Olszyna D.P., Birjmohun R., ten Kate F.J., Gouma D.J., and van der Poll T. IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 166 (2001) 6323-6331
33. Haecker F.M., Fasler-Kan E., Manasse C., Fowler B., Hertel R., and von S.D. Peritonitis in childhood: clinical relevance of cytokines in the peritoneal exudate. Eur J Pediatr Surg 16 (2006) 94-99
34. van Veen S.Q., Meijers J.C., Levi M., van Gulik T.M., and Boermeester M.A. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis. Shock 27 (2007) 534-541
35. van Veen S.Q., Levi M., van Vliet A.K., Florquin S., van Gulik T.M., and Boermeester M.A. Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis. Crit Care Med 34 (2006) 2799-2805
36. van Veen S.Q., Cheung C.W., Meijers J.C., van Gulik T.M., and Boermeester M.A. Anticoagulant and anti-inflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis. J Thromb Haemost 4 (2006) 2343-2351
37. Bell W.R. Present-day thrombolytic therapy: therapeutic agents-pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med 3 Suppl 2 (2002) S34-S44
38. Deitcher S.R., and Jaff M.R. Pharmacologic and clinical characteristics of thrombolytic agents. Rev Cardiovasc Med 3 Suppl 2 (2002) S25-S33
39. Ince A., Eroglu A., Tarhan O., and Bulbul M. Peritoneal fibrinolytic activity in peritonitis. Am J Surg 183 (2002) 67-69
40. van Goor H., Bom V.J., van der M.J., Sluiter W.J., Geerards S., van der S.W., et al. Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model. Eur Surg Res 28 (1996) 287-294